Targeting Hepatitis

Targeted delivery is an attractive method of delivering a payload to a patient in a manner that increases the concentration of the payload in specific disease site. It's indicated that drug delivery system had entered the mainstream in cancer treatment, having a bright future in the pharmaceuticals field. Creative Biolabs is one of the well-recognized experts who are professionals in targeted delivery technologies. With years of experience, our scientists offer high-quality delivery system construction and screening services to meet our clients' demands precisely.

Hepatitis

Hepatitis is inflammation developed in the liver tissue. Patients with hepatitis have a broad spectrum of presentations that range from a complete lack of symptoms to severe liver failure. Some common symptoms include yellow discoloration of the skin and whites of the eyes, poor appetite, vomiting, tiredness, abdominal pain, or diarrhea. Hepatitis presents temporary (acute) or long term (chronic) according to it lasts for less than or more than six months. Acute hepatitis may result in acute liver failure, and the chronic form may cause scarring of the liver, liver failure, or liver cancer. Virus infection is the most common cause of hepatitis worldwide. Additional causes such as heavy alcohol use, certain medications, toxins, other infections, autoimmune diseases, and non-alcoholic steatohepatitis (NASH) also can lead to hepatitis. So far, there are five major types of viral hepatitis: type A, B, C, D, and E. Generally, the treatment of hepatitis depends on the form (acute versus chronic), severity of disease, and cause.

Fig.1 Hepatitis.

Delivery System Targeting Hepatitis

Over the past years, anti-hepatitis B virus (HBV) therapy displays enhanced effectiveness against HBV. The targeted drug delivery is considered as promising parenteral administration in addition to shielding therapeutics from degradation and untimely elimination. These mechanics are drug delivery vehicles composed of soluble carriers (e.g. synthetic polymers), particulate carriers (e.g. micro- and nanoparticles), and target-specific recognition moieties (e.g. monoclonal antibodies). For instance, the cytoplasmic transduction peptide (CTP) is used in delivering the payloads to hepatocytes, an anti-HBV core single-chain variable fragment welded to CTP, followed by an assessment of its potential in HBV inhibition. This approach markedly reduced HBV DNA levels.

Besides, a series of artificial recombinant peptides, along with the cell-penetrating sequence R7 and various nucleocapsid binding subunits (NBS) have been developed. Results showed that the cell-penetrating peptides (CPPs) were highly efficiently introduced into HepG2.2.15 cells, causing obstruction of the nucleocapsid assembly, and arresting HBV release. Another novel drug delivery platform based on a CPP motif called X-Pep, is said to be applicable in having drugs delivered straight to cells specifically. Moreover, in another study, an N-acetylgalactosamine-melittin-like peptide (NAG-MLP) with a siRNA compounded to cholesterol is directed to coagulation factor 7, and validated the inhibition of HBV RNA, DNA, and proteins with a lengthy effective continuity.

Fig.2 Principles of PreS/2-21-conjugated nanoparticle with siRNA on targeted inhibition of hepatitis B virus.¹

Cationic liposomes also have been regarded as novel adjuvant systems for enhanced HBV vaccine delivery. In one previous study, asialofetuin was affixed to cationic liposomes for hepatocyte selectivity, and conjoined to it were diverse cyclodextrins and plasmid DNA for gene transfer. γ-cyclodextrin complexed with the DNA-asialofetuin liposome presented the most significant transfection efficiency with no cytotoxicity, the highest entrapment ratio of the DNA, and the ability to stabilize the membrane of the asialofetuin liposome.

Features of Our Targeted Delivery Services

• Site-specific and target-oriented delivery systems
• Minimum side-effects
• Maximum therapeutic effects
• High bioavailability
• High efficiency and time-saving

Creative Biolabs has long-term devoted to the development of targeted delivery systems. We are pleased to use our extensive experience and advanced module delivery platform to offer the best service and qualified products to satisfy each demand from our clients. Please do not hesitate to contact us for more details.

Reference

1. Gao, Lixia, et al. "PreS/2-21-Guided siRNA Nanoparticles Target to Inhibit Hepatitis B Virus Infection and Replication." Frontiers in Immunology 13 (2022): 856463.

Our services are For Research Use Only. We do not provide services to individuals.